ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Patient reported outcomes"

  • Abstract Number: 2063 • ACR Convergence 2022

    Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus

    Alfredo Aguirre1, Kimberly DeQuattro2, Patricia Katz3, Kurt Greenlund4, Kamil Barbour4, Caroline Gordon5, Cristina M Lanata6, Lindsey Criswell7, Maria Dall'Era8 and Jinoos Yazdany9, 1University of California, San Francisco, San Francisco, CA, 2University of Pennsylvania, Philadelphia, PA, 3UCSF, San Rafael, CA, 4Centers for Disease Control and Prevention, Atlanta, GA, 5Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 6NIH/NHGRI, Washington, DC, 7National Human Genome Research Institute, NIH, Bethesda, MD, 8University of California, Division of Rheumatology, San Francisco, CA, 9UCSF, San Francisco, CA

    Background/Purpose: Medication cost concerns are associated with nonadherence and poor outcomes in the general population. Prior research has described medication cost concerns in up to…
  • Abstract Number: 0199 • ACR Convergence 2022

    Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes – 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis

    Peter Taylor1, Frank Behrens2, Philip J Mease3, Dieter Wetzel4, Paul Peloso5, Nicolai Brun4, Brian Wiens6, Jan Brandt-Juergens7, Edit Drescher8, Eva Dokoupilova9, Anna Rowińska-Osuch10, Nadia Abdel- Kader Martin11 and Kurt de Vlam12, 1University of Oxford, Oxford, United Kingdom, 2Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, 3Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 4Affibody AB, Solna, Sweden, 5ACELYRIN, Naples, FL, 6ACELYRIN, Inc., Los Angeles, CA, 7Rheumatologische Schwerpunktpraxis, Berlin, Germany, 8Veszprem Megyei Csolnoky Ferenc Korhaz, Budapest, Hungary, 9Medical Plus, s.r.o. & Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Brno, Prague, Czech Republic, 10ETG Network - Rheumatology, Warsaw, Poland, 11Hospital Infanta Luisa Quiron, Rheumatology, Sevilla, Spain, 12University Hospitals Leuven, Leuven, Belgium

    Background/Purpose: Izokibep is a unique IL-17A inhibitor with high potency and small molecular size designed to overcome the limitations of monoclonal antibodies. IL-17 is a…
  • Abstract Number: 0377 • ACR Convergence 2022

    Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies

    Maria Angeles Puche Larrubia1, lourdes Ladehesa-Pineda2, María Dolores López Montilla2, Raquel Granados3, Eduardo Collantes4 and Clementina Lopez-Medina5, 1Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Granada, Spain, 2Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, 3Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, 4IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 5Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain

    Background/Purpose: The prevalence of late-onset Psoriatic Arthritis (PsA) is increasing in parallel with the progressive aging of the population. The elderly population presents a greater…
  • Abstract Number: 0699 • ACR Convergence 2022

    Effectiveness by Disease Severity in Patients with Psoriatic Arthritis Treated with Apremilast in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

    Alexis Ogdie1, Jacqueline O'Brien2, Wendi Malley2, Elizabeth Kohl2, Kate Orroth3, Yuri Klyachkin4, Myriam Cordey5 and Philip J Mease6, 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2CorEvitas, LLC, Waltham, MA, 3Amgen, Manhattan Beach, CA, 4Amgen, Lexington, KY, 5Amgen, Inc., Thousand Oaks, CA, 6Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

    Background/Purpose: Clinical trials of the efficacy and safety of apremilast have shown a significant therapeutic effect on disease activity across clinically diverse PsA patients. Given…
  • Abstract Number: 0954 • ACR Convergence 2022

    What Drives the BASDAI in Pregnant Patients with Axial Spondyloarthritis? A Pooled Analysis of Four European Pregnancy Registries

    Yvette Meissner1, Nathalie Costedoat-Chalumeau2, Rebecca Fischer-Betz3, Frauke Foerger4, Anna Molto5, Marianne Wallenius6 and Anja Strangfeld1, 1Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 2Inserm DR Paris 5, Paris, France, 3Uniklinik Duesseldorf, Duesseldorf, Germany, 4Inselspital Bern, Bern, Switzerland, 5Rheumatology Department, Cochin Hospital, APHP, Paris, France, 6St. Olav University Hospital, Trondheim, Norway

    Background/Purpose: The patient reported Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) includes the six components fatigue, neck, back or hip pain, pain or swelling in…
  • Abstract Number: 1345 • ACR Convergence 2022

    Is Perceived Stress Associated with COVID-19 or Having a Systemic Rheumatic Disease?

    Jonah Levine, Medha Barbhaiya, Vivian Bykerk, Deanna Jannat-Khah, DrPH, MSPH and Lisa Mandl, Hospital for Special Surgery, New York, NY

    Background/Purpose: The SARS-CoV-2 pandemic is a worldwide mental health crisis. We evaluated perceived stress in patients seeking care for musculoskeletal conditions, and explored associations with…
  • Abstract Number: 1495 • ACR Convergence 2022

    How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study

    Uta Kiltz1, Jan Brandt-Juergens2, Peter Kästner3, Elke Riechers4, Daniel Peterlik5, Christina Budden5 and Hans-Peter Tony6, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheumatologische Schwerpunktpraxis, Berlin, Germany, 3Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, 4Medizinische Hochschule Hannover, Hannover, Germany, 5Novartis Pharma GmbH, Nürnberg, Germany, 6Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany

    Background/Purpose: Obesity is a risk factor for worse overall health in people with ankylosing spondylitis (AS)1. The German non-interventional study AQUILA provides real-world data in…
  • Abstract Number: 2069 • ACR Convergence 2022

    Responsiveness of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort

    Aarabi Thayaparan1, Patricia Katz2, Mitra Moazzami3, Dennisse Bonilla1, Lisa Engel4, Jiandong Su1, Pooneh Akhavan5, Sherief Marzouk6, Nathalie Rozenbojm7, Nicole Anderson1, Oshrat Tayer-Shifman8, Dorcas Beaton9 and Zahi Touma1, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 2UCSF, San Rafael, CA, 3George Washington University, Washington, DC, 4University of Manitoba, Winnipeg, MB, Canada, 5Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 6University Health Network, University of Toronto, Toronto, ON, Canada, 7University Health Network, Toronto, ON, Canada, 8Meir Medical Center, Kfar Saba, Israel, 9Institute for Work & Health, Toronto, ON, Canada

    Background/Purpose: Clinicians should include Patient-Reported Outcome (PRO) measures in the assessment of lupus patients, as they are crucial in providing patient-centred care. The Patient Reported…
  • Abstract Number: 0237 • ACR Convergence 2021

    Self-perceived General Health at Start of Anti-TNF Therapy Predicts Therapeutic Response in Patients with Rheumatoid Arthritis: Analysis from the Czech Biologics Registry ATTRA

    Jakub Zavada1 and Lucie Nekvindova2, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 2Institut biostatistiky a analýz, spin-off společnost Masarykovy univerzity, Brno, Brno, Czech Republic

    Background/Purpose: SF-36 and its components, as well as other PROs have been shown to predict various disease outcomes. We hypothesized that positive responses to questions…
  • Abstract Number: 0560 • ACR Convergence 2021

    Effectiveness, Safety, Quality of Life and Patient Satisfaction with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Second Interim Analysis of a German Non-Interventional, Prospective, Multi-Center Study

    Klaus Krüger1, Frank Behrens2, Ulrich Prothmann3, Thilo Klopsch4, Lisa Blindzellner5, Olaf Behmer5, Jürgen Jobst5, Pascal Klaus5, Thomas Meng5 and Peter-Andreas Löschmann5, 1Rheumatological Practice Center, Munich, Germany, 2CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine & Pharmacology, Goethe University Hospital, Frankfurt, Germany, 3Knappschaftsklinikum Saar, Püttlingen, Germany, 4Rheumatological Practice, Neubrandenburg, Germany, 5Pfizer Pharma GmbH, Berlin, Germany

    Background/Purpose: Tofacitinib is a Janus kinase inhibitor, which is orally applied and is approved for rheumatoid arthritis among other indications. ESCALATE-RA is the first prospective,…
  • Abstract Number: 0749 • ACR Convergence 2021

    Association Between Clinically Meaningful Back Pain Improvement and Patient-reported Outcomes and Disease Activity in Patients with Ankylosing Spondylitis: Results from a Phase 2/3 Trial

    Xenofon Baraliakos1, Louis Bessette2, Carlo Salvarani3, Naijun Chen4, Ralph Lippe5, Jayeshkumar Patel4, In-Ho Song4, Patrick Zueger6 and Philippe Goupille7, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2Laval University, Québec City, QC, Canada, 3Rheumatology Unit, Azienda USL-IRCCS di Reggio Emilia and Universita di Moderna e Reggio Emilia, Reggio Emilia, Italy, 4AbbVie Inc., North Chicago, IL, 5AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, 6AbbVie Inc., Mettawa, IL, 7University hospital of Tours, Rheumatology department, Tours, France

    Background/Purpose: Back pain is the hallmark disease feature for patients (pts) with AS. However, the relationship between back pain and other patient-centric outcomes and disease…
  • Abstract Number: 0799 • ACR Convergence 2021

    Relationships of Rheumatology Care and Patient Experiences to Rheumatoid Arthritis Remission

    Kelly O'Neill1, Kathryne Marks2, Pamela Sinicrope3, Cynthia Crowson4, Elena Myasoedova3 and John Davis3, 1Rheumatoid Patient Foundation, Lutz, FL, 2Rheumatoid Patient Foundation, Boston, MA, 3Mayo Clinic, Rochester, MN, 4Mayo Clinic, Eyota, MN

    Background/Purpose: Remission is a well-established optimal outcome in rheumatoid arthritis (RA) treatment, yet a minority of patients reach this goal. There is not one recognized…
  • Abstract Number: 1156 • ACR Convergence 2021

    Impact of Treatment Experience on Patient Preferences and Disease Burden in Psoriatic Arthritis: Results from a Rheumatology Patient Research Registry

    Jessica Walsh1, Kelley Myers2, Carol Mansfield2, William Tillett3, Peter Nash4, Colton Leach2, William Nowell5, Kelly Gavigan5, Patrick Zueger6, Erin McDearmon-Blondell7 and Alexis Ogdie-Beatty8, 1Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, 2RTI Health Solutions, Research Triangle Park, NC, 3Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 4Griffith University, Brisbane, Australia, 5Global Healthy Living Foundation, Upper Nyack, NY, 6AbbVie Inc., Mettawa, IL, 7AbbVie Inc., Elmhurst, IL, 8University of Pennsylvania, Philadelphia, PA

    Background/Purpose: To optimize patient-provider shared decision-making, it is important to understand patients’ experience with psoriatic arthritis (PsA) and its treatment, including how treatment experience may…
  • Abstract Number: 1279 • ACR Convergence 2021

    Impact of Active Lupus Nephritis in Patient-Reported Outcomes from a Latin American, Multicenter Lupus Cohort

    Romina Nieto1, Eduardo Ferreira Borba2, Eugenia Settecasse3, Diana Fernandez-Avila4, Laura Maurelli5, Carla Gobbi6, Verónica Saurit7, Fernando Arizpe8, Julieta Daniele9, Maria Constanza Bertolaccini10, Eduardo Kerzberg11, María de los Ángeles Gargiulo12, Anabella Rodriguez13, Ana Carolina Londe14, Vitalina Sousa Barbosa15, Andrese Aline Gasparin16, Carolina Albanez A Cunha Andrade17, Luciana Parente Costa Seguro18, Lucas Victoria de Oliveira Martins19, Oscar Neira20, Carolina Llanos21, Loreto Massardo22, Antonio Iglesias23, Ivana Nieto Aristizábal24, Gloria Vasquez25, Paul Mendez-Patarroyo26, Lizeth de la Hoz Rueda23, José Martínez Pérez27, Reyna Sánchez Briones28, Mario Pérez Cristóbal29, Eduardo Martin-Nares30, Yaneli Juárez-Vicuña31, Yelitza Gonzalez Bello32, Jorge González García33, Dionicio Galarza-Delgado34, Marcos Vázquez35, Patricia Langjarh35, Magaly Alva Linares36, Cristina Reategui-Sokolova37, Armando Calvo Quirós38, Edral Rodriguez39, Ricardo Robaina40, Martín Rebella41, Graciela Alarcn42, Ashley Orillion43, Chetan Karyekar44, Federico Zazzetti45 and Guillermo Pons-Estel46, 1Hospital Provincial de Rosario, Rosario, Argentina, 2Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, 3Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Rosario, Argentina, 4Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5Hospital Italiano de Córdoba, Córdoba, Argentina, 6Hospital Córdoba, Córdoba, Argentina, 7Hospital Privado Universitario de Córdoba, Córdoba, 8Hospital HIGA San Martín, La Plata, Argentina, 9Sanatorio Británico, Rosario, Argentina, 10Hospital Padilla, San Miguel de Tucumán, Argentina, 11Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, 12Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, 13CEMIC, Buenos Aires, Argentina, 14Universidade Estadual de Campinas, Faculdade de Ciencias Médicas, São Paulo, Brazil, 15Hospital das Clinicas, Univerisad Federal de Goias, Goias, Brazil, 16Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, 17Universidad Federal de Pernambuco, Recife, Brazil, 18Hospital Das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil, 19Universidad Federal São Paulo, São Paulo, Brazil, 20Hospital del Salvador, Santiago, Chile, 21Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile, 22Universidad San Sebastián, Santiago, Chile, 23Clínica de la Costa Ltda., Barranquilla, Colombia, 24Fundación Valle del Lili, Cali, Colombia, 25Division of rheumatology, Universidad de Antioquia, Medellin, Colombia, 26Reumavance Group, Rheumatology section, Department of Internal Medicine, Fundación Santa Fe de Bogotá University Hospital; Department of Internal Medicine, School of Medicine, Universidad de Los Andes, Bogota, Colombia, 27Hospital Luis Vernaza, Guayaquil, Ecuador, 28Centro Médico La Raza, Ciudad de México, Mexico, 29Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico, 30Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 31Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, 32Centro de Estudios de investigación Básica y Clínica S.C, Guadalajara, Mexico, 33Hospital Central Dr. Ignacio Morones Prieto, San Luís Potosí, Mexico, 34Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico, 35Hospital de Clínicas I, Asunción, Paraguay, 36Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, 37Hospital Guillermo Almenara Irigoyen, Lima, Peru, 38Hospital Cayetano Heredia, Lima, Peru, 39Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, 40Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, 41Unidad de Enfermedades Autoinmunes Sistémicas de Médica Uruguay Corporación de Asistencia Médica (MUCAM); Unidad de Enfermedades Autoinmunes Sistémicas del Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, 42University of Alabama at Birmingham, Birmingham, AL, 43Global Commercial Strategic Organisation, Johnson and Johnson, Horsham, PA, 44Janssen R&D, Spring House, PA, 45Medical Affairs, Jan-Cil Argentina, Buenos Aires, Argentina, 46Grupo Oroño. Centro Regional de Enfermedades Autoinmunes y Reumaticas (GO-CREAR), Rosario, Argentina

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple and heterogeneous clinical manifestations that may negatively affect these patients’ quality of life…
  • Abstract Number: 1592 • ACR Convergence 2021

    ACT for Lupus: Pilot Study of a Novel Acceptance and Commitment Therapy (ACT) Online Program to Support Patients with Lupus During the COVID-19 Pandemic

    Tessa Englund1, Saira Sheikh2, Becki Cleveland1, Emily McCormick1, Crystal Schiller3 and Teresa Dickson1, 1Thurston Arthritis Research Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, 2University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, 3University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic disease associated with significant symptom burden, including fatigue, anxiety, depression, pain, and negative impacts on health-related quality…
  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 43
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology